Literature DB >> 18262716

Hedgehog signalling in androgen independent prostate cancer.

Greg Shaw1, Anna M Price, Elena Ktori, Isabelle Bisson, Patricia E Purkis, Siobhan McFaul, R Tim D Oliver, David M Prowse.   

Abstract

OBJECTIVES: Androgen-deprivation therapy effectively shrinks hormone-naïve prostate cancer, both in the prostate and at sites of distant metastasis. However prolonged androgen deprivation generally results in relapse and androgen-independent tumour growth, which is inevitably fatal. The molecular events that enable prostate cancer cells to proliferate in reduced androgen conditions are poorly understood. Here we investigate the role of Hedgehog signalling in androgen-independent prostate cancer (AIPC).
METHODS: Activity of the Hedgehog signalling pathway was analysed in cultured prostate cancer cells, and circulating prostate tumour cells were isolated from blood samples of patients with AIPC.
RESULTS: AIPC cells were derived through prolonged culture in reduced androgen conditions, modelling hormone therapy in patients, and expressed increased levels of Hedgehog signalling proteins. Exposure of cultured AIPC cells to cyclopamine, which inhibits Hedgehog signalling, resulted in inhibition of cancer cell growth. The expression of the Hedgehog receptor PTCH and the highly prostate cancer-specific gene DD3(PCA3) was significantly higher in circulating prostate cancer cells isolated from patients with AIPC compared with samples prepared from normal individuals. There was an association between PTCH and DD3(PCA3) expression and the length of androgen-ablation therapy.
CONCLUSIONS: Our data are consistent with reports implicating overactivity of Hedgehog signalling in prostate cancer and suggest that Hedgehog signalling contributes to the androgen-independent growth of prostate cancer cells. As systemic anti-Hedgehog medicines are developed, the Hedgehog pathway will become a potential new therapeutic target in advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18262716     DOI: 10.1016/j.eururo.2008.01.070

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

Review 1.  Future directions in castrate-resistant prostate cancer therapy.

Authors:  Emmanuel S Antonarakis; Michael A Carducci
Journal:  Clin Genitourin Cancer       Date:  2010-12-01       Impact factor: 2.872

2.  Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.

Authors:  Benjamin L Maughan; Daniel L Suzman; Brandon Luber; Hao Wang; Stephanie Glavaris; Robert Hughes; Rana Sullivan; Rana Harb; Karim Boudadi; Channing Paller; Mario Eisenberger; Angelo Demarzo; Ashely Ross; Emmanuel S Antonarakis
Journal:  Cancer Chemother Pharmacol       Date:  2016-11-08       Impact factor: 3.333

3.  High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer.

Authors:  Daniel L Suzman; Emmanuel S Antonarakis
Journal:  Clin Genitourin Cancer       Date:  2013-11-14       Impact factor: 2.872

4.  Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling.

Authors:  Vassiliki Tzelepi; Maria Karlou; Sijin Wen; Anh Hoang; Christopher Logothetis; Patricia Troncoso; Eleni Efstathiou
Journal:  Histopathology       Date:  2011-06       Impact factor: 5.087

Review 5.  Cell mates: paracrine and stromal targets for prostate cancer therapy.

Authors:  Pavel Sluka; Ian D Davis
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

6.  Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.

Authors:  Mengqian Chen; Michael A Feuerstein; Elina Levina; Prateek S Baghel; Richard D Carkner; Matthew J Tanner; Michael Shtutman; Francis Vacherot; Stéphane Terry; Alexandre de la Taille; Ralph Buttyan
Journal:  Mol Cancer       Date:  2010-04-26       Impact factor: 27.401

7.  Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers.

Authors:  Bin Xu; Gusheng Tang; Chengwu Xiao; Linhui Wang; Qing Yang; Yinghao Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

8.  Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.

Authors:  Pramod S Gowda; Jianhong D Deng; Sweta Mishra; Abhik Bandyopadhyay; Sitai Liang; Shu Lin; Devalingam Mahalingam; Lu-Zhe Sun
Journal:  Mol Cancer Res       Date:  2013-08-29       Impact factor: 5.852

9.  Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model.

Authors:  Han-Hsin Chang; Bo-Yie Chen; Chia-Yung Wu; Zih-Jay Tsao; Ying-Yu Chen; Chin-Pao Chang; Chi-Rei Yang; David Pei-Cheng Lin
Journal:  J Biomed Sci       Date:  2011-01-18       Impact factor: 8.410

10.  SHH-N non-canonically sustains androgen receptor activity in androgen-independent prostate cancer cells.

Authors:  Diana Trnski; Maja Sabol; Sanja Tomić; Ivan Štefanac; Milanka Mrčela; Vesna Musani; Nikolina Rinčić; Matea Kurtović; Tina Petrić; Sonja Levanat; Petar Ozretić
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.